Tiziana Life Sciences Share Discussion Threads

[jpuff] 23/8/2019 15:58

We've a share price performance Neil Woodford would be envious of !!!

[asmodeus] 23/8/2019 15:34

sp down 9% today, at 5.10 pm.

[asmodeus] 21/8/2019 13:50

I’m trying to buy shares in our local funeral directors, for the same reason, Sten. :)

[stenick] 21/8/2019 13:26

I am not contemplating selling, at the moment,would like to see Tils succeed and make some life changing discoveries that I may need in the future.

[jpuff] 21/8/2019 10:42

It's certainly quiet here but that's not necessarily a bad sign. Still waiting patiently and after all this time why contemplate selling as the news flow is getting more encouraging!

[stenick] 21/8/2019 10:36

Yes Asmo it would be nice but as people have said they could be stringing us along.:-)

[asmodeus] 20/8/2019 20:30

Hope you're right, Sten.

[stenick] 20/8/2019 16:55

Right my monies on next week there being news. I think it will be good news,like,they’;ve been negotiating hard with big pharma about the take out price and they’ve finally come to a realistic valuation of, I would say around £2billion as after all it’s is a multi billion £ market and the foralumab performed excellently in the trial. IMO.

[stenick] 07/8/2019 16:29

Still alive and kicking, and to be fair the price drop from £2.40p was inevitable as they had along way to go with no revenue,and obviously had to sell shares cheaper to attract the investment,but now a few years down the line as the trials are confirming the products, values can change and after all I think it is quite normal to spend millions of £ on drug trials which have to be done and we all know they allways seem to take longer than first thought.
But the reality is the product(Milciclib) seems to work very well,not a complete cure but gives the cancer a good knock without making the patient feel to bad and 5years+ is pretty good at keeping the tumour ‘under control’for some is remarkable.All proved by proper trials unlike other investments I’ve been in.And the biggy foralumab to come.So you ask me why the drop in price,i think people just get fed up with waiting, but you have to be in it to win it because an $86+billion market per year with proven products is not to be ignored imho dyor

[stenick] 07/8/2019 08:11

Who knows Asmo but perhaps when news is released on foralumab trial things might change.

[asmodeus] 07/8/2019 07:36

I'm very well thanks, Stten, and hope You are too. Still don't understand the price drop. Are the shares being offered at a big discount to the previous price? Or is the potential disbelieved?

[stenick] 06/8/2019 19:52

Asmodeus how are you.
Well I’m astounded that the price didn’t collapse with all those sells but then seeing what’s to come I’m so excited for the future all looks pretty good to me and the science is all backed up independently,so I’m still confident that when it all sinks in people will realise the potential after all a big market is there for the taking, and the products give a better quality of life,so to me I think that everyone’s a winner.

[jpuff] 06/8/2019 18:22

Good opportunity to top up imho

[asmodeus] 06/8/2019 17:50

Looks very impressive, Sten., so why the price fall?

[stenick] 06/8/2019 17:09

Over $86billion market foralumab.

[jpuff] 06/8/2019 08:36

Sounding very promising, we await the MRI scans.

[stenick] 06/8/2019 08:18

Not what I was expecting,but inevitable.



Worth a listen

[jpuff] 06/8/2019 07:57

Tiziana Life Sciences PLC Proposed U.S. Public OfferingSource: UK Regulatory (RNS & others)TIDMTILSRNS Number : 8979HTiziana Life Sciences PLC06 August 2019THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTIONTiziana Announces Publication of Registration Statement on Form F-1 andProposed U.S. Public Offering of ADSsNew York and London, August 6, 2019 - Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the commencement of an underwritten public offering in the United States of American Depositary Shares ("ADSs"), representing ordinary shares of nominal value GBP0.03 each in the capital of the Company ("Ordinary Shares") on the NASDAQ Global Market (the "Offering"). There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The price for the Offering has not yet been determined.All ADSs to be sold in the Offering will be offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering will be within existing shareholder authorities.ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the representative of the underwriters in the Offering.The Offering is being made only by means of a prospectus, which, for the avoidance of doubt, will not constitute a "prospectus" for the purposes of the Prospectus Regulation (as defined below) and has not been reviewed by any competent authority in any Member State (as defined below).When available, copies of the preliminary prospectus relating to and describing the terms of the Offering may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22(nd) Floor, New York, New York 10004, by telephone at [phone], or by email at [e-mail]. Electronic copies of the preliminary prospectus will also be available on the website of the SEC at www.sec.gov.A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The person who arranged for the release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.About Tiziana Life Sciences plcTiziana Life Sciences is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. We believe Foralumab is the only fully human anti-CD3 mAb in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as NASH, primary biliary cholangitis (PBS), ulcerative colitis, MS, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.For readers in the European Economic AreaIn any member state in the European Economic Area (each, a "Member State"), this announcement is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Regulation. The term "Prospectus Regulation" means Regulation (EU) 2017/1129.For readers in the United KingdomThis announcement, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) in connection with the securities which are the subject of the Offering described in this announcement or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc.") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs offered in the Offering are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Ordinary Shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.ENDFor further enquiries: Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder [phone] ThinkEquity, a division of Fordham Financial Management, Inc. Ramnarain Jaigobind / Priyanka Mahajan [phone] Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner [phone] Shore Capital (Broker) Andy Crossley / Antonio Bossi [phone] This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.ENDOUPPAMLTMBJMMIL(END) Dow Jones NewswiresAugust 06, 2019 02:00 ET (06:00 GMT)

[stenick] 05/8/2019 17:38

I’m so excited and I just can’t hide it, come on, I know patience is a virtue, but the suspense is ‘killing’; me.

[stenick] 31/7/2019 12:09

Tomorrow is the first week in August, should have some news on our £21billion market drug. Gla

[stenick] 24/7/2019 17:17

Oh well let’s wait and see. I for one feel positive on this unlike you which I totally understand.

[supernumerary] 24/7/2019 14:46

Yes, the hope of all these baby bios is that they'll find a sugar daddy who'll pick up all the bills without taking too much of the profit. Rarely happens though - they mostly go on raising more and more money at lower and lower prices until either they get a really strong result and a big fish bites, or, more often, they just fade away to nothing. As I understand it Tiziana already has a bit of history like that...

[stenick] 24/7/2019 12:46

Hope some big pharma will see potential here and snap it up quick, which I think was the original plan at the beginning, and of course they have stated previously that manufacture of the drugs is no problem, but of course they would not have the resources as yet to distribute and market the drugs when approved, so come on big pharma an opportunity awaits.

[stenick] 24/7/2019 12:31

So a hell of a long way to go yet.

[supernumerary] 24/7/2019 11:03

I've not been involved (as an investor, not a practitioner!) in a case where a drug was approved on the basis of single arm trials, although I do believe it's possible. But it's early days here, they would normally have two Phase 3s to complete before approval, and one or more of those may be full multi-arm, placebo-controlled, double-blind trials.